Qingdao Saber Technology Pharmaceutical: difference between revisions
Diff·revision 33 → 34·14:13, 2 Dec 2025
Difference between revision 33 and revision 34 of Qingdao Saber Technology Pharmaceutical. 12 lines changed; the page grew by 1,054 bytes.
| Revision 33 — 13:33, 23 Nov 2025 BlindSampleBrid (talk) ce, tighten prose 8,771 bytes ±0 | Revision 34 — 14:13, 2 Dec 2025 VerifyVesna (talk) lead should summarise the body, not add to it 9,825 bytes +1,054 | ||
|---|---|---|---|
| 61 | The PeptidePedia tally records 668 self-reported submissions to July 2026 — below the median for these articles. Recurring complaints concern documentation consistency; recurring positive themes are price and delivery.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} | 61 | The PeptidePedia tally records 668 self-reported submissions to July 2026 — below the median for these articles. Recurring complaints concern documentation consistency; recurring positive themes are price and delivery.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} |
| 62 | 62 | ||
| + | 63 | === How this tally should be read === | |
| + | 64 | The reception figure above is a mean of self-reported submissions to PeptidePedia. It is '''weak evidence''' and is subject to three limitations that apply to every such figure on this wiki: | |
| + | 65 | ||
| + | 66 | * '''Self-selection.''' People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions. | |
| + | 67 | * '''It measures reception, not quality.''' Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly. | |
| + | 68 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} | |
| + | 69 | ||
| 63 | == Regulatory position and legal status == | 70 | == Regulatory position and legal status == |
| 64 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | 71 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} |
| ⋮ | ⋮ | ||
| 76 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 83 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |
| 77 | 84 | ||
| + | 85 | == Further reading == | |
| + | 86 | * [[Project:Vendor notability]] — the criteria under which this article exists, and what supplier articles may not contain. | |
| + | 87 | * [[Project:Sourcing guidelines]] — how test reports and community tallies are cited on this wiki. | |
| + | 88 | ||
| 78 | == See also == | 89 | == See also == |
| 79 | * [[Certificate of analysis]] | 90 | * [[Certificate of analysis]] |
| ⋮ | ⋮ | ||
| 83 | * [[Research use only]] | 94 | * [[Research use only]] |
| 84 | * [[Peptide supply chain]] | 95 | * [[Peptide supply chain]] |
| + | 96 | * [[Blind sampling]] | |
| 85 | 97 | ||
| 86 | {{DEFAULTSORT:Qingdao Saber Technology Pharmaceutical}} | 98 | {{DEFAULTSORT:Qingdao Saber Technology Pharmaceutical}} |